Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.

Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P.

Alzheimers Res Ther. 2015 Jul 1;7(1):40. doi: 10.1186/s13195-015-0124-3. eCollection 2015.

PMID:
26136856
2.

Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness.

Gustavsson AM, Stomrud E, Abul-Kasim K, Minthon L, Nilsson PM, Hansson O, Nägga K.

Cerebrovasc Dis Extra. 2015 May 20;5(2):41-51. doi: 10.1159/000377710. eCollection 2015 May-Aug.

3.

Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients.

Torisson G, van Westen D, Stavenow L, Minthon L, Londos E.

BMC Geriatr. 2015 Jun 16;15:65. doi: 10.1186/s12877-015-0066-4.

4.

Associations of central and brachial blood pressure with cognitive function: a population-based study.

Nilsson ED, Elmståhl S, Minthon L, Nilsson PM, Pihlsgård M, Nägga K.

J Hum Hypertens. 2015 Apr 16. doi: 10.1038/jhh.2015.33. [Epub ahead of print]

PMID:
25880593
5.

CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study.

Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, Leyhe T, Bürger K, Taniguchi M, Urakami K, Lista S, Dubois B, Blennow K, Hampel H.

Alzheimers Dement. 2015 Mar 21. pii: S1552-5260(15)00063-1. doi: 10.1016/j.jalz.2014.12.006. [Epub ahead of print]

PMID:
25804998
6.

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K.

Alzheimers Dement. 2014 Dec 19. pii: S1552-5260(14)02863-5. doi: 10.1016/j.jalz.2014.10.009. [Epub ahead of print]

PMID:
25533203
7.

Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index.

Hall A, Mattila J, Koikkalainen J, Lötjonen J, Wolz R, Scheltens P, Frisoni G, Tsolaki M, Nobili F, Freund-Levi Y, Minthon L, Frölich L, Hampel H, Visser PJ, Soininen H.

Curr Alzheimer Res. 2015;12(1):69-79.

PMID:
25523428
8.

An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Hölttä M, Minthon L, Hansson O, Holmén-Larsson J, Pike I, Ward M, Kuhn K, Rüetschi U, Zetterberg H, Blennow K, Gobom J.

J Proteome Res. 2015 Feb 6;14(2):654-63. doi: 10.1021/pr501076j. Epub 2014 Dec 22.

PMID:
25490617
9.

Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.

Wattmo C, Londos E, Minthon L.

Clin Interv Aging. 2014 Nov 14;9:1951-62. doi: 10.2147/CIA.S71709. eCollection 2014.

10.

Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.

Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A.

J Alzheimers Dis. 2015;44(4):1313-22. doi: 10.3233/JAD-142025.

PMID:
25420549
11.

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.

Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, Blennow K, Öhrfelt A.

Mol Neurodegener. 2014 Nov 23;9:53. doi: 10.1186/1750-1326-9-53.

12.

Pro-inflammatory cytokines reduce the proliferation of NG2 cells and increase shedding of NG2 in vivo and in vitro.

Wennström M, Janelidze S, Bay-Richter C, Minthon L, Brundin L.

PLoS One. 2014 Oct 6;9(10):e109387. doi: 10.1371/journal.pone.0109387. eCollection 2014.

13.

Nonlinear association between pulse wave velocity and cognitive function: a population-based study.

Nilsson ED, Elmståhl S, Minthon L, Nilsson PM, Pihlsgård M, Tufvesson E, Nägga K.

J Hypertens. 2014 Nov;32(11):2152-7; discussion 2157. doi: 10.1097/HJH.0000000000000329.

PMID:
25275244
14.

Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels.

Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson M, Westrin A, Minthon L, Hansson O, Träskman-Bendz L, Brundin L.

Acta Psychiatr Scand. 2015 Apr;131(4):269-78. doi: 10.1111/acps.12339. Epub 2014 Sep 24.

PMID:
25251027
15.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

Wattmo C, Londos E, Minthon L.

BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.

16.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
17.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
18.

Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia.

Nägga K, Hansson O, van Westen D, Minthon L, Wennström M.

J Alzheimers Dis. 2014;42(4):1435-41. doi: 10.3233/JAD-141200.

PMID:
25024336
19.

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.

Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E.

BMJ Open. 2014 Jul 3;4(7):e005158. doi: 10.1136/bmjopen-2014-005158.

20.

Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up.

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2014;38(5-6):286-99. doi: 10.1159/000362926. Epub 2014 Jul 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk